NEWS

Pharmasyntez Group, one of the leading biopharmaceutical companies, has announced plans to launch a production of a comprehensive range of medical products for dialysis at Kaluga starting from 2025

Pharmasyntez Group, one of the leading biopharmaceutical companies, has announced plans to launch a production of a comprehensive range of medical products for dialysis at its new Pharmasyntez-Medtech facility in Kaluga starting from 2025.

Up until 2023, almost 90% of all medical and pharmaceutical products needed for dialysis were produced outside of the Russian Federation. In 2023-2024, the Pharmasyntez Group made an extraordinary effort to effectively bring the products bearing the trademarks Diasolution and Diasolution PD to market, thereby addressing the growing shortfall in peritoneal dialysis solutions. This was the first instance of complete import substitution to provide Russian patients with top-notch domestic products for dialysis.

The chronic kidney disease, a socially significant illness, is one of the top 20 "killer diseases" of mankind. Patients in the terminal stages of the disease require renal replacement therapy on a daily basis; dialysis and kidney transplants are the two primary options. In 2023, over 64,000 Russians were undergoing renal replacement therapy in 2023; the number of patients requiring this treatment is rising yearly.

Vikram Punia, President of the Pharmasyntez Group stated: "Today, due to the complicated geopolitical situation, it is especially important to ensure drug safety for patients with socially significant diseases. Encouraging a full supply of high-quality dialysis goods for Russian patients is one of the top goals of the Pharmasyntez Group's industrial development. We are currently getting ready to open our new plant in Kaluga in 2025 and start producing the first peritoneal dialysis medical devices made in the country. This is our contribution to Russia's advancement of contemporary home dialysis techniques. We are currently developing a full range of products for chronic hemodialysis and extracorporeal hemocorrection”.

In recent years, there has been a focus on the growing number of kidney transplant recipients and patients undergoing peritoneal dialysis, the only kind of at-home dialysis available in Russia, while considering strategies for developing renal replacement therapy in the nation. Establishing a thorough import substitution program for pharmaceutical and medicinal products for all forms of dialysis is a critical step in ensuring drug safety for Russian patients and giving them access to cutting-edge therapeutic approaches.

Nikolai Panikarovsky, Chief Executive Officer of Pharmasyntez-Medtech LLC stated: “Currently, Pharmasyntez-Medtech is at the stage of launching a new project for import-substituting production of medical devices for dialysis. The project's first stage will be launching the production of consumables and medical devices and equipment under the NOVADIAL brand for automated and continuous ambulatory peritoneal dialysis. Pharmasyntez-Medtech's production capacity will enable us to meet the nation's whole demand for these items. Additionally, we are developing dialysis solutions, dialyzers, lines, concentrates made domestically”.